Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Influence of IFN-gamma and its receptors in human breast cancer

Authors: Ignacio García-Tuñón, Mónica Ricote, Antonio Ruiz A, Benito Fraile, Ricardo Paniagua, Mar Royuela

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Interferons are a group of proteins that trigger multiple responses including prevention of viral replication, inhibition of cell growth, and modulation of cell differentiation. In different mammary carcinoma cell lines IFNγ induces growth arrest at mid-G1. At the present there are no in vivo studies in human breast. The aim of this study was to investigate the expression patterns of IFNγ and its two receptors (IFNγ-Rα and IFNγ-Rβ) by Western blot and immunohistochemistry, in order to elucidate its role in the different types of human breast cancer (in situ and infiltrative).

Methods

Immunohistochemical and semiquantitative study of IFNγ, its receptors types (IFNγ-Rα and IFNγ-Rβ), cell proliferation (proliferating cell nuclear antigen, also named PCNA), and apoptosis (TUNEL method) was carried between the three breast groups (fibrocystic lesions, in situ tumors and infiltrating tumors).

Results

In the three groups of patients, IFNγ and IFNγ-Rα immunoreactions appeared in the cytoplasm while IFNγ-Rβ also was found in the nucleus. The optical density to IFNγ was higher in in situ carcinoma than in benign and infiltrating tumors. When we observed IFNγ-Rα, the optical density was lower in infiltrating carcinoma than in benign and in situ tumors (the higher density). To IFNγ-Rβ, the optical density was similar in the three group samples. In tumor samples PCNA and TUNEL index was significantly higher; than in benign diseases. PCNA index increased with the malignance. No significant differences were found between cancer types to TUNEL. IFNγ could be a potential therapeutic tool in breast cancer. However, tumor cells are able to escape from the control of this cytokine in the early tumor stages; this is probably due to a decreased expression of IFNγ, or also to an alteration of either its receptors or some transduction elements.

Conclusion

We conclude that the decrease in the % positive samples that expressed IFNγ and IFNγ-Rα together with the nuclear localization of IFNγ-Rβ, could be a tumoral cell response, although perhaps insufficient to inhibit the uncontrolled cell proliferation. Perhaps, IFNγ might be unable to activate p21 to stop the cell cycle, suggesting a possible participation in breast cancer development.
Appendix
Available only for authorised users
Literature
1.
go back to reference Borden E, Balkwill F: Preclinical and clinical studies of interferons and interferons inducers in breast cancer. Cancer. 1999, 85: 134-144. 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C.CrossRef Borden E, Balkwill F: Preclinical and clinical studies of interferons and interferons inducers in breast cancer. Cancer. 1999, 85: 134-144. 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C.CrossRef
3.
go back to reference Soh J, Donnely R, Kotenko S, Mariano T, Cook J, Wang N, Emanuel S, Schawartz B, Miki T, Petska S: Identification and sequece of an accessory factor required for activation of the human interferon-γ receptor. Cell. 1994, 76: 793-802. 10.1016/0092-8674(94)90354-9.CrossRefPubMed Soh J, Donnely R, Kotenko S, Mariano T, Cook J, Wang N, Emanuel S, Schawartz B, Miki T, Petska S: Identification and sequece of an accessory factor required for activation of the human interferon-γ receptor. Cell. 1994, 76: 793-802. 10.1016/0092-8674(94)90354-9.CrossRefPubMed
4.
go back to reference Linehan W, LaRocca R, Stein C, Walther M, Cooper M, Weiss G, Choyke P, Cassidy J, Uhrich M, Myer C: Use of suramin in treatment of patients with advanced prostate carcinoma. J Urol. 1990, 143: 221- Linehan W, LaRocca R, Stein C, Walther M, Cooper M, Weiss G, Choyke P, Cassidy J, Uhrich M, Myer C: Use of suramin in treatment of patients with advanced prostate carcinoma. J Urol. 1990, 143: 221-
5.
go back to reference Aguet M, Dembic Z, Merlin G: Molecular cloning and expresión of human interferon-γ receptor. Cell. 1988, 55: 273-280. 10.1016/0092-8674(88)90050-5.CrossRefPubMed Aguet M, Dembic Z, Merlin G: Molecular cloning and expresión of human interferon-γ receptor. Cell. 1988, 55: 273-280. 10.1016/0092-8674(88)90050-5.CrossRefPubMed
6.
go back to reference Royuela M, de Miguel MP, Ruiz A, Fraile B, Arenas MI, Romo E, Paniagua R: Interferon-gamma and its receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw. 2000, 11 (1): 119-127.PubMed Royuela M, de Miguel MP, Ruiz A, Fraile B, Arenas MI, Romo E, Paniagua R: Interferon-gamma and its receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw. 2000, 11 (1): 119-127.PubMed
7.
go back to reference Havat B, Jetten A: γ-interferon indeuces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ. 1996, 7: 289-300. Havat B, Jetten A: γ-interferon indeuces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ. 1996, 7: 289-300.
8.
go back to reference Muller H, Flury N, Liu R, Scheidegger S, Eppenberger U: Tumor necrosis factor and interfeeron are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. Eur J Cancer. 1996, 32A: 2312-2318. 10.1016/S0959-8049(96)00273-0.CrossRef Muller H, Flury N, Liu R, Scheidegger S, Eppenberger U: Tumor necrosis factor and interfeeron are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. Eur J Cancer. 1996, 32A: 2312-2318. 10.1016/S0959-8049(96)00273-0.CrossRef
9.
go back to reference Fujishima H, Nakano S, Tatsumoto T, Masumoto N, Niho Y: Interferon-α and -γ inhibit the growth and neoplastic potencial of v-src-transformed human epithelial cells by reducing Src tyrosine kinase activity. Int J Cancer. 1998, 76: 423-429. 10.1002/(SICI)1097-0215(19980504)76:3<423::AID-IJC22>3.0.CO;2-A.CrossRefPubMed Fujishima H, Nakano S, Tatsumoto T, Masumoto N, Niho Y: Interferon-α and -γ inhibit the growth and neoplastic potencial of v-src-transformed human epithelial cells by reducing Src tyrosine kinase activity. Int J Cancer. 1998, 76: 423-429. 10.1002/(SICI)1097-0215(19980504)76:3<423::AID-IJC22>3.0.CO;2-A.CrossRefPubMed
10.
go back to reference Wadler S, Schwartz E: Anti neoplasic activity of combination of interferon and cytotoxic agents against experimental and human malignaces: a review. Cancer Res. 1990, 50: 3473-3486.PubMed Wadler S, Schwartz E: Anti neoplasic activity of combination of interferon and cytotoxic agents against experimental and human malignaces: a review. Cancer Res. 1990, 50: 3473-3486.PubMed
11.
go back to reference Kirchhoff S, Hauser H: Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene. 1999, 18: 3725-3736. 10.1038/sj.onc.1202704.CrossRefPubMed Kirchhoff S, Hauser H: Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene. 1999, 18: 3725-3736. 10.1038/sj.onc.1202704.CrossRefPubMed
12.
go back to reference Ruiz-Ruiz C, Muñoz-Pinedo C, Lopez-Rivas A: Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 2000, 60: 5673-5680.PubMed Ruiz-Ruiz C, Muñoz-Pinedo C, Lopez-Rivas A: Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 2000, 60: 5673-5680.PubMed
13.
go back to reference Dighe A, Richards E, Old L, Schereiber R: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-gamma receptors. Immunity. 1994, 1: 447-456. 10.1016/1074-7613(94)90087-6.CrossRefPubMed Dighe A, Richards E, Old L, Schereiber R: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-gamma receptors. Immunity. 1994, 1: 447-456. 10.1016/1074-7613(94)90087-6.CrossRefPubMed
14.
go back to reference Doherty G, Tsung K, McCluskey B, Norton J: Endogenous interferon gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res. 1996, 64: 68-74. 10.1006/jsre.1996.0308.CrossRefPubMed Doherty G, Tsung K, McCluskey B, Norton J: Endogenous interferon gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res. 1996, 64: 68-74. 10.1006/jsre.1996.0308.CrossRefPubMed
15.
go back to reference Habif D, Ozzello C, De la Rosa C, Cantell K, Lattes R: Regression of skin recurrences of breast cancer treated with intralesional injections of natural interferon alpha and gamma. Cancer Invest. 1995, 13: 165-173.CrossRefPubMed Habif D, Ozzello C, De la Rosa C, Cantell K, Lattes R: Regression of skin recurrences of breast cancer treated with intralesional injections of natural interferon alpha and gamma. Cancer Invest. 1995, 13: 165-173.CrossRefPubMed
16.
go back to reference Macheledt J, Buzdar A, Hotobagyi G, Frye D, Gutterman J, Holmes F: Phase II evaluation of interferon added to tamoxifen in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991, 18: 165-170. 10.1007/BF01990032.CrossRefPubMed Macheledt J, Buzdar A, Hotobagyi G, Frye D, Gutterman J, Holmes F: Phase II evaluation of interferon added to tamoxifen in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991, 18: 165-170. 10.1007/BF01990032.CrossRefPubMed
17.
go back to reference Seymour L, Bezwoda W: Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biological effects of two growth modulator. Br J Cancer. 1993, 68: 352-356.CrossRefPubMedPubMedCentral Seymour L, Bezwoda W: Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biological effects of two growth modulator. Br J Cancer. 1993, 68: 352-356.CrossRefPubMedPubMedCentral
18.
go back to reference Gooch J, Herrera R, Yee D: The role of p21 in interferon γ-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 2000, 11: 335-342.PubMed Gooch J, Herrera R, Yee D: The role of p21 in interferon γ-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 2000, 11: 335-342.PubMed
19.
go back to reference Hemmi S, Bohni R, Stark G, Dimarco F, Aguet M: A novel member of the interferon receptor family complements functionally of the murine interferon-γ receptor in human cells. Cell. 1994, 76: 803-810. 10.1016/0092-8674(94)90355-7.CrossRefPubMed Hemmi S, Bohni R, Stark G, Dimarco F, Aguet M: A novel member of the interferon receptor family complements functionally of the murine interferon-γ receptor in human cells. Cell. 1994, 76: 803-810. 10.1016/0092-8674(94)90355-7.CrossRefPubMed
20.
go back to reference Zhang M, Guo R, Zhai Y, Yang D: LIGHT sensitizes IFN-γ-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of antiapoptotic Bcl-2 family members. Cancer Lett. 2003, 195: 201-210.CrossRefPubMed Zhang M, Guo R, Zhai Y, Yang D: LIGHT sensitizes IFN-γ-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of antiapoptotic Bcl-2 family members. Cancer Lett. 2003, 195: 201-210.CrossRefPubMed
21.
go back to reference Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltratingand and in situ human breast carcinoma. Histopathology. 2005, 47: 82-89. 10.1111/j.1365-2559.2005.02178.x.CrossRefPubMed Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltratingand and in situ human breast carcinoma. Histopathology. 2005, 47: 82-89. 10.1111/j.1365-2559.2005.02178.x.CrossRefPubMed
22.
go back to reference Subramaniam PS, Green MM, Larkin J, Torres BA, Johnson HM: Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by heterologous nuclear localization sequence. J Interferon Cytokine Res. 2001, 21 (11): 951-959. 10.1089/107999001753289569.CrossRefPubMed Subramaniam PS, Green MM, Larkin J, Torres BA, Johnson HM: Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by heterologous nuclear localization sequence. J Interferon Cytokine Res. 2001, 21 (11): 951-959. 10.1089/107999001753289569.CrossRefPubMed
23.
go back to reference Doherty G, Boucher L, Sorenson K, Lowney J: Interferon regulatory factor expresión in human breast cancer. Ann Surg. 2001, 233: 623-629. 10.1097/00000658-200105000-00005.CrossRefPubMedPubMedCentral Doherty G, Boucher L, Sorenson K, Lowney J: Interferon regulatory factor expresión in human breast cancer. Ann Surg. 2001, 233: 623-629. 10.1097/00000658-200105000-00005.CrossRefPubMedPubMedCentral
24.
go back to reference Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH: p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 2217-2224.PubMed Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH: p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 2217-2224.PubMed
25.
go back to reference Jiang T, Jiang H, Song XS, Li XC, Li QL: P53 expression and its clinical significance in prostatic carcinoma. Zhonghua Nan Ke Xue. 2005, 11: 448-451.PubMed Jiang T, Jiang H, Song XS, Li XC, Li QL: P53 expression and its clinical significance in prostatic carcinoma. Zhonghua Nan Ke Xue. 2005, 11: 448-451.PubMed
26.
go back to reference Hobeika A, Etienne W, Cruz P, Subramaniam P, Johnson H: IFN-γ induction of p21waf1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer. 1998, 77: 138-145. 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9.CrossRefPubMed Hobeika A, Etienne W, Cruz P, Subramaniam P, Johnson H: IFN-γ induction of p21waf1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer. 1998, 77: 138-145. 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9.CrossRefPubMed
27.
go back to reference Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Cell cycle control related proteins (p53, p21 and Rb) and trandforming growth factor β (TGF-β) in benign and carcinomatous (In situ and infiltrating) human breast cancer: implications in malignant transformation. Cancer Invest. 2006, 24: 1-7. 10.1080/07357900500524314.CrossRef Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Cell cycle control related proteins (p53, p21 and Rb) and trandforming growth factor β (TGF-β) in benign and carcinomatous (In situ and infiltrating) human breast cancer: implications in malignant transformation. Cancer Invest. 2006, 24: 1-7. 10.1080/07357900500524314.CrossRef
28.
go back to reference Wang X, Li N, Liu B, Qui J, Chen T, Cao X: Silencing of human phosphatidylethanolamine-binding protein sensitizes breast cancer cells to tumor necrosis factor alpha-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005, 11: 7545-7553. 10.1158/1078-0432.CCR-05-0879.CrossRefPubMed Wang X, Li N, Liu B, Qui J, Chen T, Cao X: Silencing of human phosphatidylethanolamine-binding protein sensitizes breast cancer cells to tumor necrosis factor alpha-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005, 11: 7545-7553. 10.1158/1078-0432.CCR-05-0879.CrossRefPubMed
29.
go back to reference Fransen L, Van Der Heyden J, Ruysschaert R, Fiers W: Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma an a variety of normal and transformated human cell line. Eur J Cancer Clin Oncol. 1986, 22: 419-426. 10.1016/0277-5379(86)90107-0.CrossRefPubMed Fransen L, Van Der Heyden J, Ruysschaert R, Fiers W: Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma an a variety of normal and transformated human cell line. Eur J Cancer Clin Oncol. 1986, 22: 419-426. 10.1016/0277-5379(86)90107-0.CrossRefPubMed
30.
go back to reference Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Role of tumor necrosis factor-α in human benign breast lesions and tumors (in situ and infiltrating). Cancer Sci. 2006, 97: 1044-1049. 10.1111/j.1349-7006.2006.00277.x.CrossRefPubMed Garcia-Tuñon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Role of tumor necrosis factor-α in human benign breast lesions and tumors (in situ and infiltrating). Cancer Sci. 2006, 97: 1044-1049. 10.1111/j.1349-7006.2006.00277.x.CrossRefPubMed
31.
go back to reference Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223.CrossRefPubMedPubMedCentral Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223.CrossRefPubMedPubMedCentral
32.
go back to reference Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 2003, 63 (19): 6424-6431.PubMed Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 2003, 63 (19): 6424-6431.PubMed
33.
go back to reference Ruiz-Ruiz C, Lopez-Rivas : Mitochondria-dependent and – independent mechanism in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) apoptosis are both regulated by interferon-γ in human breast tumuor cells. Biochem J. 2002, 365: 825-832.CrossRefPubMedPubMedCentral Ruiz-Ruiz C, Lopez-Rivas : Mitochondria-dependent and – independent mechanism in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) apoptosis are both regulated by interferon-γ in human breast tumuor cells. Biochem J. 2002, 365: 825-832.CrossRefPubMedPubMedCentral
Metadata
Title
Influence of IFN-gamma and its receptors in human breast cancer
Authors
Ignacio García-Tuñón
Mónica Ricote
Antonio Ruiz A
Benito Fraile
Ricardo Paniagua
Mar Royuela
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-158

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine